Chaminda Salgado

Highly experienced CMC Leader, with 14 years experience in CMC biological assets and 9 years in Cell & Gene therapies, ensuring the smooth flow of programs from Lead development through to commercialisation and beyond. Well versed in process improvement by automation of both lab procedures and data, with a strong back ground in analytical development. Held Leadership positions in large Pharma as well as small Biotechs and Contract manufacture and Research. Career highlight was being part of the leadership team that launched Strimvelis, the first gene therapy for children. Currently involved with Autologous, and Allogeneic cell therapies, Lenti and AAV production, and RNA vaccines.